Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-NY005 PET-CT Imaging in CLDN18.2 Positive Solid Tumors
NCT04989010Unknown
- Sponsor
- The Affiliated Hospital of Jiangnan University
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Open-label, single-arm trial of 89Zr-NY005 in gastric cancer (GC), esophageal cancer and pancreatic cancer (PC), sponsored by The Affiliated Hospital of Jiangnan University. Primary endpoints: Evaluation of tissue distribution of 89Zr-Anti-CLDN18.2 mAbs(NY005) at 1 year, Pharmacokinetic analysis of 89Zr-Anti-CLDN18.2 mAbs (NY005) at 1 year and 1 more. Status: unknown.
02
Drugs
89Zr-NY005
03
Conditions
gastric cancer (GC)esophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04989010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989010.